Abstract
The EARS2 nuclear gene encodes mitochondrial glutamyl-tRNA synthetase, a member of the class I family of aminoacyl-tRNA synthetases (aaRSs) that plays a crucial role in mitochondrial protein biosynthesis by catalyzing the charging of glutamate to mitochondrial tRNA(Glu). Pathogenic EARS2 variants have been associated with a rare mitochondrial disorder known as leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL). The targeted sequencing of 150 nuclear genes encoding respiratory chain complex subunits and proteins implicated in the oxidative phosphorylation (OXPHOS) function was performed. The oxygen consumption rate (OCR), and the extracellular acidification rate (ECAR), were measured. The enzymatic activities of Complexes I-V were analyzed spectrophotometrically. We describe a patient carrying two heterozygous EARS2 variants, c.376C>T (p.Gln126*) and c.670G>A (p.Gly224Ser), with infantile-onset disease and a severe clinical presentation. We demonstrate a clear defect in mitochondrial function in the patient’s fibroblasts, suggesting the molecular mechanism underlying the pathogenicity of these EARS2 variants. Experimental validation using patient-derived fibroblasts allowed an accurate characterization of the disease-causing variants, and by comparing our patient’s clinical presentation with that of previously reported cases, new clinical and radiological features of LTBL were identified, expanding the clinical spectrum of this disease.
Highlights
Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative phosphorylation (OXPHOS) system and can arise due to defects in genes in theGenes 2020, 11, 1028; doi:10.3390/genes11091028 www.mdpi.com/journal/genesGenes 2020, 11, 1028 nuclear or mitochondrial DNA [1]
next-generation sequencing (NGS) analysis enabled the identification of two compound heterozygous variants in EARS2 (NM_001083614.1) in our patient (Figure 1): variant c.670G>A (p.Gly224Ser) has been previously described in a patient with mild LTBL [10], while c.376C>T (p.Gln126*) has not to date been included in any human genetic variation database
The identified EARS2 variants were analyzed in silico to determine the degree of evolutionary conservation, predicted pathogenicity, functional consequences, and minor allele frequency (MAF)
Summary
Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative phosphorylation (OXPHOS) system and can arise due to defects in genes in theGenes 2020, 11, 1028; doi:10.3390/genes11091028 www.mdpi.com/journal/genesGenes 2020, 11, 1028 nuclear or mitochondrial DNA (nDNA and mtDNA, respectively) [1]. Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction of the oxidative phosphorylation (OXPHOS) system and can arise due to defects in genes in the. The remaining components of mtDNA replication, transcription, and translation processes, including tRNA maturation, initiation and elongation factors, ribosomal proteins, and aminoacyl-tRNA synthetases (mt-aaRSs), are encoded by nDNA, synthesized in the cytosol, and imported into the mitochondria [3,4]. NDNA-encoded mt-aaRS genes produce enzymes that play an important role in protein synthesis by charging tRNAs with their cognate amino acid and ensuring the correct protein translation [5,6]. Genetic defects in EARS2 may lead to combined OXPHOS deficiency (MIM#614924), an autosomal recessive neurologic disorder caused by either compound heterozygous or homozygous variants. Defects in EARS2 have been associated with a specific clinical syndrome called leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) [10]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have